跳至主要内容
临床试验/NCT02062190
NCT02062190已完成2 期

Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal

Federal University of Rio Grande do Sul1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
19
试验地点
1
主要终点
Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.

研究概览

简要总结

Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

详细描述

Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.

排除标准

  • Patients will be excluded from the study:
  • Have a diagnosis of diabetes
  • Use other antipsychotic drugs, clozapine beyond
  • Using medicines for diabetes or dyslipidaemia
  • Accept not participate in any stage of the research.

研究组 & 干预措施

resveratrol

Active Comparator

干预措施: resveratrol (Drug)

corn starch

Placebo Comparator

(10 patients) 100mg 2x/day

1 month

干预措施: resveratrol (Drug)

结局指标

主要结局

Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.

时间窗: 1 month

Assessment of cardiovascular risk will be realized by measurement of cytokine levels (IL-12p70, IL-6, IL-10, IL-1b, IL-8 and TNF-α), C-reactive protein and cholesterol levels (total cholesterol, LDL, HDL, triglycerides) in patients with schizophrenia before and after supplementation with resveratrol or placebo.

次要结局

  • Cognitive performance will be assessed with a battery of cognitive tests and BPRS (brief psychiatric rating scale) to assess symptoms.(1 month)

研究者

发起方
Federal University of Rio Grande do Sul
申办方类型
Other
责任方
Principal Investigator
主要研究者

Karine Zortéa

Master

Federal University of Rio Grande do Sul

研究点 (1)

Loading locations...

相似试验